{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:13:00Z","timestamp":1790842380387,"version":"4.1.0"},"reference-count":217,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Brigham Young University Simmons Center for Cancer Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>For nearly three decades, chimeric antigen receptors (CARs) have captivated the interest of researchers seeking to find novel immunotherapies to treat cancer. CARs were first designed to work with T cells, and the first CAR T cell therapy was approved to treat B cell lymphoma in 2017. Recent advancements in CAR technology have led to the development of modified CARs, including multi-specific CARs and logic gated CARs. Other immune cell types, including natural killer (NK) cells and macrophages, have also been engineered to express CARs to treat cancer. Additionally, CAR technology has been adapted in novel approaches to treating autoimmune disease and other conditions and diseases. In this article, we review these recent advancements in alternative CAR therapies and design, as well as their mechanisms of action, challenges in application, and potential future directions.<\/jats:p>","DOI":"10.3390\/biomedicines10071493","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T10:39:13Z","timestamp":1656153553000},"page":"1493","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1688-4990","authenticated-orcid":false,"given":"Carlos","family":"Moreno","sequence":"first","affiliation":[{"name":"Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4319-0476","authenticated-orcid":false,"given":"Christopher","family":"Haynie","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3541-1507","authenticated-orcid":false,"given":"Abigail","family":"Cheever","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3688-2191","authenticated-orcid":false,"given":"K.","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.3747\/co.27.5223","article-title":"A review of cancer immunotherapy: From the past, to the present, to the future","volume":"27","author":"Esfahani","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","article-title":"Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids","volume":"174","author":"Dijkstra","year":"2018","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"618387","DOI":"10.3389\/fimmu.2020.618387","article-title":"Befriending the hostile tumor microenvironment in CAR T-cell therapy","volume":"11","author":"Lindo","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.it.2019.02.003","article-title":"Targeting tumor-associated macrophages in cancer","volume":"40","author":"Pathria","year":"2019","journal-title":"Trends Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-1085-0","article-title":"Regulatory T cells in tumor microenvironment: New mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Dapash, M., Castro, B., Hou, D., and Lee-Chang, C. (2021). Current immunotherapeutic strategies for the treatment of glioblastoma. Cancers, 13.","DOI":"10.3390\/cancers13184548"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00428-019-02538-4","article-title":"Recent success and limitations of immune checkpoint inhibitors for cancer: A lesson from melanoma","volume":"474","author":"Ottaviano","year":"2019","journal-title":"Virchows Arch."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2018.09.007","article-title":"Immune checkpoint inhibition overcomes ADCP-induced immunosuppression by macrophages","volume":"175","author":"Su","year":"2018","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Vaddepally, R.K., Kharel, P., Pandey, R., Garje, R., and Chandra, A.B. (2020). Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers, 12.","DOI":"10.3390\/cancers12030738"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"eabd4344","DOI":"10.1126\/sciimmunol.abd4344","article-title":"A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity","volume":"6","author":"Boulch","year":"2021","journal-title":"Sci. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm827","article-title":"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15","volume":"9","author":"Brentjens","year":"2003","journal-title":"Nat. Med."},{"key":"ref_18","first-page":"669","article-title":"FDA approves first CAR T therapy","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41417-021-00307-7","article-title":"TCR-like CARs and TCR-CARs targeting neoepitopes: An emerging potential","volume":"28","author":"Poorebrahim","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41392-021-00462-1","article-title":"Nanobody-based chimeric antigen receptor T cells designed by CRISPR\/Cas9 technology for solid tumor immunotherapy","volume":"6","author":"Mo","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy. molecular therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Methods Clin. Dev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: From CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1002\/acg2.84","article-title":"TRUCKS, the fourth-generation CAR T cells: Current developments and clinical translation","volume":"3","author":"Chmielewski","year":"2020","journal-title":"Adv. Cell Gene Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"112512","DOI":"10.1016\/j.biopha.2021.112512","article-title":"Therapeutic potential of CAR T cell in malignancies: A scoping review","volume":"146","author":"Mehrabadi","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"101070","DOI":"10.1016\/j.tranon.2021.101070","article-title":"Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs","volume":"14","author":"Moghanloo","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12943-019-1057-4","article-title":"Next generation chimeric antigen receptor T cells: Safety strategies to overcome toxicity","volume":"18","author":"Yu","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large b-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor t-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The tumor microenvironment innately modulates cancer progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nm.4258","article-title":"Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity","volume":"23","author":"Ghosh","year":"2017","journal-title":"Nat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"ofaa121","DOI":"10.1093\/ofid\/ofaa121","article-title":"Infectious complications following CD19 chimeric antigen receptor t-cell therapy for children, adolescents, and young adults","volume":"7","author":"Vora","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","article-title":"Logic-Gated ROR1 chimeric antigen receptor expression rescues t cell-mediated toxicity to normal tissues and enables selective tumor targeting","volume":"35","author":"Srivastava","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor t cell therapy","volume":"25","author":"Frey","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41434-021-00246-w","article-title":"Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany","volume":"28","author":"Albinger","year":"2021","journal-title":"Gene Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tmrv.2019.08.003","article-title":"Anti-CD19 CAR t-cell therapy for b-cell non-hodgkin lymphoma","volume":"34","author":"Abramson","year":"2019","journal-title":"Transfus. Med. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40261-021-01100-y","article-title":"Comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 vs physician\u2019s choice of therapy in the long-term follow-up of POLLUX, CASTOR, and EQUULEUS clinical trials for the treatment of patients with relapsed or refractory multiple myeloma","volume":"42","author":"Weisel","year":"2022","journal-title":"Clin. Drug Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4049\/jimmunol.131.1.244","article-title":"B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes","volume":"131","author":"Nadler","year":"1983","journal-title":"J. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jcyt.2016.10.009","article-title":"Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma","volume":"19","author":"Oelsner","year":"2017","journal-title":"Cytotherapy"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"324","DOI":"10.7861\/clinmedicine.18-4-324","article-title":"Cancer immunotherapy with CAR-T cells\u2014Behold the future","volume":"18","author":"Graham","year":"2018","journal-title":"Clin. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: Rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"ref_55","first-page":"332","article-title":"FDA approves first BCMA-targeted CAR-T cell therapy","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11899-019-00537-5","article-title":"Multi-specific CAR targeting to prevent antigen escape","volume":"14","author":"Walsh","year":"2019","journal-title":"Curr. Hematol. Malign- Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Cronk, R.J., Zurko, J., and Shah, N.N. (2020). Bispecific chimeric antigen receptor T cell therapy for B cell malignancies and multiple myeloma. Cancers, 12.","DOI":"10.3390\/cancers12092523"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: A phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Shalabi, H., Qin, H., Su, A., Yates, B., Wolters, P.L., Steinberg, S.M., Ligon, J.A., Silbert, S., D\u00e9D\u00e9, K., and Benzaoui, M. CD19\/22 CAR T-cells in children and young adults with B-ALL: Phase I results and development of a novel bicistronic CAR. Blood, 2022. in press.","DOI":"10.1182\/blood.2022015795"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2386187","DOI":"10.1155\/2018\/2386187","article-title":"Immunotherapy with CAR-modified T cells: Toxicities and overcoming strategies","volume":"2018","author":"Sun","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","article-title":"Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy","volume":"12","author":"Han","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3389\/fonc.2020.01362","article-title":"Dual targeting to overcome current challenges in multiple myeloma CAR T-cell treatment","volume":"10","author":"Mutis","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"780399","DOI":"10.3389\/fimmu.2021.780399","article-title":"Implementing logic gates for safer immunotherapy of cancer","volume":"12","author":"Savanur","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1\u2013 and CTLA-4\u2013Based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal chimeric antigen receptors for multiplexed and logical control of T cell responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41467-021-21078-7","article-title":"Engineering advanced logic and distributed computing in human CAR immune cells","volume":"12","author":"Cho","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1785608","DOI":"10.1080\/2162402X.2020.1785608","article-title":"Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy","volume":"9","author":"Feldmann","year":"2020","journal-title":"OncoImmunology"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Kittel-Boselli, E., Soto, K.E.G., Loureiro, L.R., Hoffmann, A., Bergmann, R., Arndt, C., Koristka, S., Mitwasi, N., Kegler, A., and Bartsch, T. (2021). Targeting acute myeloid leukemia using the RevCAR platform: A programmable, switchable and combinatorial strategy. Cancers, 13.","DOI":"10.3390\/cancers13194785"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering customized cell sensing and response behaviors using synthetic notch receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"eabe7378","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-17970-3","article-title":"Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function","volume":"11","author":"Salzer","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1126\/science.aba6527","article-title":"Designed protein logic to target cells with precise combinations of surface antigens","volume":"369","author":"Lajoie","year":"2020","journal-title":"Science"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/bs.apcsb.2022.02.001","article-title":"Natural killer cell-based strategies for immunotherapy of cancer","volume":"129","author":"Abreu","year":"2022","journal-title":"Advances in Protein Chemistry and Structural Biology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1182\/bloodadvances.2020002547","article-title":"Next-generation cell therapies: The emerging role of CAR-NK cells","volume":"4","author":"Basar","year":"2020","journal-title":"Blood Adv."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/CJI.0000000000000286","article-title":"Anti-\u03b1FR CAR-engineered NK-92 cells display potent cytotoxicity against \u03b1FR-positive ovarian cancer","volume":"42","author":"Ao","year":"2019","journal-title":"J. Immunother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3389\/fimmu.2019.00957","article-title":"Human CAR NK cells: A new non-viral method allowing high efficient transfection and strong tumor cell killing","volume":"10","author":"Ingegnere","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3389\/fimmu.2020.02028","article-title":"Highly efficient generation of transgenically augmented CAR NK cells overexpressing CXCR4","volume":"11","author":"Jamali","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4263520","DOI":"10.1155\/2018\/4263520","article-title":"Combination therapy with EpCAM-CAR-NK-92 cells and regorafenib against human colorectal cancer models","volume":"2018","author":"Zhang","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.3389\/fimmu.2019.03123","article-title":"High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia","volume":"10","author":"Bexte","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.4049\/jimmunol.1400330","article-title":"DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy","volume":"194","author":"Cartellieri","year":"2015","journal-title":"J. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/ni1325","article-title":"NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells","volume":"7","author":"Upshaw","year":"2006","journal-title":"Nat. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"108587","DOI":"10.1016\/j.intimp.2022.108587","article-title":"Novel insights in CAR-NK cells beyond CAR-T cell technology; Promising advantages","volume":"106","author":"Ebrahimiyan","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbrc.2020.01.053","article-title":"Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer","volume":"524","author":"Cao","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_92","first-page":"303","article-title":"CAR-NK cells for cancer therapy: Molecular redesign of the innate antineoplastic response","volume":"22","year":"2021","journal-title":"Curr. Gene Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.3389\/fimmu.2020.01534","article-title":"Cytotoxicity of donor natural killer cells to allo-reactive t cells are related with acute graft-vs.-host-disease following allogeneic stem cell transplantation","volume":"11","author":"Sheng","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Lupo, K.B., and Matosevic, S. (2019). Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy. Cancers, 11.","DOI":"10.3390\/cancers11060769"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.it.2016.09.005","article-title":"Harnessing NK cell memory for cancer immunotherapy","volume":"37","author":"Fehniger","year":"2016","journal-title":"Trends Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood.2020006619","article-title":"CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas","volume":"136","author":"Gang","year":"2020","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ni.2032","article-title":"Natural killer cell memory","volume":"12","author":"Paust","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/17534259211001512","article-title":"Human NK cells: From development to effector functions","volume":"27","author":"Arachchige","year":"2021","journal-title":"Innate Immun."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"814334","DOI":"10.3389\/fimmu.2022.814334","article-title":"The interaction of HLA-C1\/KIR2DL2\/L3 promoted KIR2DL2\/L3 single-positive\/NKG2C-positive natural killer cell reconstitution, raising the incidence of aGVHD after hematopoietic stem cell transplantation","volume":"13","author":"Zuo","year":"2022","journal-title":"Front Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"732135","DOI":"10.3389\/fimmu.2021.732135","article-title":"Current perspectives on \u201coff-the-shelf\u201d allogeneic NK and CAR-NK cell therapies","volume":"12","author":"Heipertz","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-55239-y","article-title":"Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells","volume":"9","author":"Herrera","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/sctm.20-0459","article-title":"Hematopoietic Stem Cell- and induced pluripotent stem cell-derived CAR-NK cells as reliable cell-based therapy solutions","volume":"10","author":"Arias","year":"2021","journal-title":"Stem Cells Transl. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/cas.14374","article-title":"Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer\/innate lymphoid cells","volume":"111","author":"Ueda","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11060-019-03311-y","article-title":"Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function","volume":"145","author":"Caruso","year":"2019","journal-title":"J. Neurooncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/hum.2017.157","article-title":"Optimization of human NK cell manufacturing: Fully automated separation, improved Ex Vivo expansion using IL-21 with autologous feeder cells, and generation of anti-CD123-CAR-expressing effector cells","volume":"28","author":"Oberschmidt","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"100678","DOI":"10.1016\/j.blre.2020.100678","article-title":"Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies","volume":"44","author":"Tanaka","year":"2020","journal-title":"Blood Rev."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3389\/fimmu.2017.00465","article-title":"Natural killer cells in graft-versus-host-disease after allogeneic hematopoietic cell transplantation","volume":"8","author":"Simonetta","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00262-010-0904-3","article-title":"A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer","volume":"59","author":"Iliopoulou","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood-2011-01-329508","article-title":"Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients","volume":"118","author":"Curti","year":"2011","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e002128","DOI":"10.1136\/jitc-2020-002128","article-title":"Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells","volume":"9","author":"Lee","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-022-00364-6","article-title":"CAR-NK cells for cancer immunotherapy: From bench to bedside","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomark. Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/5562630","article-title":"Selective cytotoxicity of single and dual anti-CD19 and anti-CD138 chimeric antigen receptor-natural killer cells against hematologic malignancies","volume":"2021","author":"Luanpitpong","year":"2021","journal-title":"J. Immunol. Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.immuni.2020.05.001","article-title":"Single-cell RNA sequencing of tumor-infiltrating NK cells reveals that inhibition of transcription factor HIF-1\u03b1 unleashes NK cell activity","volume":"52","author":"Ni","year":"2020","journal-title":"Immunity"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1002\/jcp.26429","article-title":"Macrophage plasticity, polarization, and function in health and disease","volume":"233","author":"Mohammadian","year":"2018","journal-title":"J. Cell Physiol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/cmi.12580","article-title":"Macrophages: Sentinels and regulators of the immune system","volume":"18","author":"Franken","year":"2016","journal-title":"Cell. Microbiol."},{"key":"ref_120","first-page":"1","article-title":"Pattern recognition receptors in health and diseases","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/1568010054022024","article-title":"Macrophages in inflammation","volume":"4","author":"Fujiwara","year":"2005","journal-title":"Curr. Drug Targets Inflamm. Allergy"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1194637","article-title":"Fate mapping analysis reveals that adult microglia derive from primitive macrophages","volume":"330","author":"Ginhoux","year":"2010","journal-title":"Science"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.immuni.2013.04.004","article-title":"Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes","volume":"38","author":"Hashimoto","year":"2013","journal-title":"Immunity"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/imm.12451","article-title":"Tissue-resident macrophages: Then and now","volume":"144","author":"Davies","year":"2015","journal-title":"Immunology"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-physiol-022516-034339","article-title":"Macrophage polarization","volume":"79","author":"Murray","year":"2017","journal-title":"Annu. Rev. Physiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cellimm.2013.01.010","article-title":"Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin","volume":"281","author":"Jaguin","year":"2013","journal-title":"Cell. Immunol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.4049\/jimmunol.178.8.5245","article-title":"Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: Implications for CSF blockade in inflammation","volume":"178","author":"Fleetwood","year":"2007","journal-title":"J. Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/0008-5472.CAN-20-2990","article-title":"Macrophage-based approaches for cancer immunotherapy","volume":"81","author":"Anderson","year":"2021","journal-title":"Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1084\/jem.176.1.287","article-title":"Interleukin 4 potently enhances murine macrophage mannose receptor activity: A marker of alternative immunologic macrophage activation","volume":"176","author":"Stein","year":"1992","journal-title":"J. Exp. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.immuni.2010.05.007","article-title":"Alternative activation of macrophages: Mechanism and functions","volume":"32","author":"Gordon","year":"2010","journal-title":"Immunity"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.4049\/jimmunol.151.12.7151","article-title":"Modulation of murine macrophage function by IL-13","volume":"151","author":"Doherty","year":"1993","journal-title":"J. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"52294","DOI":"10.18632\/oncotarget.10561","article-title":"TGF-beta induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_134","first-page":"3282","article-title":"Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer","volume":"6","author":"Ueno","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","article-title":"Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0167-5699(92)90008-U","article-title":"The origin and function of tumor-associated macrophages","volume":"13","author":"Mantovani","year":"1992","journal-title":"Immunol. Today"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.4049\/jimmunol.155.4.2240","article-title":"IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response","volume":"155","author":"Kim","year":"1995","journal-title":"J. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"762","DOI":"10.4049\/jimmunol.164.2.762","article-title":"Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages","volume":"164","author":"Sica","year":"2000","journal-title":"J. Immunol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.4049\/jimmunol.163.11.6251","article-title":"Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells","volume":"163","author":"Loercher","year":"1999","journal-title":"J. Immunol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-017-0430-2","article-title":"Tumor-associated macrophages: From basic research to clinical application","volume":"10","author":"Yang","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3389\/fimmu.2019.01611","article-title":"Tuning the tumor myeloid microenvironment to fight cancer","volume":"10","author":"Jahchan","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1158\/1078-0432.CCR-13-0525","article-title":"Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: A role for targeting the CCL2\/CCR2 axis","volume":"19","author":"Sanford","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/hep.26094","article-title":"Recruitment of a myeloid cell subset (CD11b\/Gr1 mid) via CCL2\/CCR2 promotes the development of colorectal cancer liver metastasis","volume":"57","author":"Zhao","year":"2013","journal-title":"Hepatology"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1172\/JCI82152","article-title":"LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment","volume":"125","author":"Nakada","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature21409","article-title":"Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages","volume":"543","author":"Guerriero","year":"2017","journal-title":"Nature"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","article-title":"Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma","volume":"23","author":"Orillion","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.celrep.2016.04.084","article-title":"Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis","volume":"15","author":"Georgoudaki","year":"2016","journal-title":"Cell Rep."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1038\/s41467-018-07387-4","article-title":"Integrin CD11b activation drives anti-tumor innate immunity","volume":"9","author":"Schmid","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells","volume":"539","author":"Rausch","year":"2016","journal-title":"Nature"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3Kgamma is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e36688","DOI":"10.7554\/eLife.36688","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Morrissey","year":"2018","journal-title":"eLife"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41416-019-0578-3","article-title":"Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix","volume":"121","author":"Zhang","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1146\/annurev.cellbio.17.1.463","article-title":"How matrix metalloproteinases regulate cell behavior","volume":"17","author":"Sternlicht","year":"2001","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1158\/1538-7445.AM2020-3254","article-title":"MOTO-CARs (TM): A novel macrophage-based chimeric antigen receptor technology","volume":"80","author":"Townsend","year":"2020","journal-title":"Cancer Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"783305","DOI":"10.3389\/fimmu.2021.783305","article-title":"Engineered CAR-macrophages as adoptive immunotherapies for solid tumors","volume":"12","author":"Sloas","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.immuni.2020.06.014","article-title":"Immune sensing mechanisms that discriminate self from altered self and foreign nucleic acids","volume":"53","author":"Bartok","year":"2020","journal-title":"Immunity"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/gt.2012.61","article-title":"Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory protein","volume":"20","author":"Bobadilla","year":"2012","journal-title":"Gene Ther."},{"key":"ref_161","first-page":"A141","article-title":"128\u2005Development of an M1-polarized, non-viral chimeric antigen receptor macrophage (CAR-M) platform for cancer immunotherapy","volume":"8","author":"Ohtani","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"113727","DOI":"10.1016\/j.jviromet.2019.113727","article-title":"A simple and efficient method for the generation of a porcine alveolar macrophage cell line for high-efficiency Porcine reproductive and respiratory syndrome virus 2 infection","volume":"274","author":"Wang","year":"2019","journal-title":"J. Virol. Methods"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-60506-4","article-title":"mRNA transfection-induced activation of primary human monocytes and macrophages: Dependence on carrier system and nucleotide modification","volume":"10","author":"Moradian","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00983-2","article-title":"Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions","volume":"13","author":"Zhang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1399-0039.2005.00434.x","article-title":"Mechanisms of lymphocyte migration in autoimmune disease","volume":"66","author":"Norman","year":"2005","journal-title":"Tissue Antigens"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"ltaa006","DOI":"10.1093\/immadv\/ltaa006","article-title":"CAR-T cells leave the comfort zone: Current and future applications beyond cancer","volume":"1","author":"Mazzi","year":"2021","journal-title":"Immunother. Adv."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.molimm.2013.11.013","article-title":"Contributions of B cells to lupus pathogenesis","volume":"62","author":"Sang","year":"2014","journal-title":"Mol. Immunol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii\/iii systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2215\/CJN.01070118","article-title":"Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis","volume":"13","author":"Mendez","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/imj.13136","article-title":"Single-dose rituximab in refractory lupus nephritis","volume":"46","author":"Kotagiri","year":"2016","journal-title":"Intern. Med. J."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"eaav1648","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2016.12.007","article-title":"Adoptive transfer of mRNA-transfected T cells redirected against diabetogenic CD8 T cells can prevent diabetes","volume":"25","author":"Fishman","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1196\/annals.1447.040","article-title":"Developing a novel model system to target insulin-reactive CD8 T cells","volume":"1150","author":"Scott","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jaut.2018.08.004","article-title":"Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes","volume":"96","author":"Zhang","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1073\/pnas.1323436111","article-title":"Monoclonal antibody blocking the recognition of an insulin peptide\u2013MHC complex modulates type 1 diabetes","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2567.2012.03564.x","article-title":"B-cell receptor: From resting state to activate","volume":"136","author":"Treanor","year":"2012","journal-title":"Immunology"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","article-title":"Mechanisms of disease: Pemphigus and bullous pemphigoid","volume":"11","author":"Hammers","year":"2016","journal-title":"Annu. Rev. Pathol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1212\/WNL.94.15_supplement.2769","article-title":"MuSK Chimeric Autoantibody receptor (CAAR) T cells for antigen specific immunotherapy of Myasthenia Gravis (2769)","volume":"94","author":"Oh","year":"2020","journal-title":"Neurology"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1182\/blood-2013-01-478669","article-title":"Progress toward inducing immunologic tolerance to factor VIII","volume":"121","author":"Scott","year":"2013","journal-title":"Blood"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","article-title":"F8 gene mutation type and inhibitor development in patients with severe hemophilia A: Systematic review and meta-analysis","volume":"119","author":"Gouw","year":"2012","journal-title":"Blood"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/bloodadvances.2018018556","article-title":"Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo","volume":"2","author":"Parvathaneni","year":"2018","journal-title":"Blood Adv."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"603237","DOI":"10.3389\/fimmu.2020.603237","article-title":"Chimeric antigen receptor based therapy as a potential approach in autoimmune diseases: How close are we to the treatment?","volume":"11","author":"Seifalian","year":"2020","journal-title":"Front Immunol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41590-018-0120-4","article-title":"Regulatory T cells in autoimmune disease","volume":"19","author":"Hafler","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"108409","DOI":"10.1016\/j.intimp.2021.108409","article-title":"CAR Treg: A new approach in the treatment of autoimmune diseases","volume":"102","author":"Beheshti","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1158\/1078-0432.CCR-10-3347","article-title":"Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease","volume":"17","author":"Beres","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.4049\/jimmunol.1700520","article-title":"The plasticity and stability of regulatory T cells during viral-induced inflammatory lesions","volume":"199","author":"Bhela","year":"2017","journal-title":"J. Immunol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1053\/j.gastro.2009.01.049","article-title":"Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor","volume":"136","author":"Elinav","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J. Neuroinflamm."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J. Autoimmun."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2016-07-727834","article-title":"FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII","volume":"129","author":"Yoon","year":"2017","journal-title":"Blood"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3389\/fimmu.2020.00693","article-title":"Suppression of FVIII-specific memory B cells by chimeric BAR receptor-engineered natural regulatory T cells","volume":"11","author":"Pohl","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V96.3.785.015k10_785_793","article-title":"Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects","volume":"96","author":"Mitsuyasu","year":"2000","journal-title":"Blood"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood.V84.9.2878.2878","article-title":"Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors","volume":"84","author":"Roberts","year":"1994","journal-title":"Blood"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1006\/mthe.2002.0611","article-title":"A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy","volume":"5","author":"Deeks","year":"2002","journal-title":"Mol. Ther."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/COH.0000000000000485","article-title":"Chimeric antigen receptor T-cell approaches to HIV cure","volume":"13","author":"Kuhlmann","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.1128\/JVI.00474-15","article-title":"Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity","volume":"89","author":"Liu","year":"2015","journal-title":"J. Virol."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Zmievskaya, E., Valiullina, A., Ganeeva, I., Petukhov, A., Rizvanov, A., and Bulatov, E. (2021). Application of CAR-T cell therapy beyond oncology: Autoimmune diseases and viral infections. Biomedicines, 9.","DOI":"10.3390\/biomedicines9010059"},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Ma, M., Badeti, S., Geng, K., and Liu, D. (2020). Efficacy of targeting SARS-CoV-2 by CAR-NK Cells. bioRxiv.","DOI":"10.1101\/2020.08.11.247320"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.gastro.2007.11.002","article-title":"T Cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes","volume":"134","author":"Bohne","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jcyt.2018.02.002","article-title":"HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice","volume":"20","author":"Kruse","year":"2018","journal-title":"Cytotherapy"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2014-308316","article-title":"Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein","volume":"65","author":"Sautto","year":"2016","journal-title":"Gut"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3389\/fmicb.2016.00844","article-title":"Cytomegalovirus-infected cells resist T cell mediated killing in an HLA-recognition independent manner","volume":"7","author":"Proff","year":"2016","journal-title":"Front. Microbiol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"468","DOI":"10.7555\/JBR.28.20140066","article-title":"T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo","volume":"28","author":"Tang","year":"2014","journal-title":"J. Biomed. Res."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"9341","DOI":"10.2147\/OTT.S221040","article-title":"CD137 Co-stimulation improves the antitumor effect of LMP1-specific chimeric antigen receptor T cells in vitro and in vivo","volume":"12","author":"Tang","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1874357901307010028","article-title":"An influenza virus M2 protein specific chimeric antigen receptor modulates influenza A\/WSN\/33 H1N1 infection in vivo","volume":"7","author":"Talbot","year":"2013","journal-title":"Open Virol. J."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"10660","DOI":"10.1073\/pnas.1312789111","article-title":"Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection","volume":"111","author":"Kumaresan","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nri1745","article-title":"Dectin-1: A signalling non-TLR pattern-recognition receptor","volume":"6","author":"Brown","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.ymthe.2019.09.021","article-title":"CARdiac immunotherapy: T cells engineered to treat the fibrotic heart","volume":"27","author":"Vagnozzi","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.2174\/092986707781696573","article-title":"The role of lymphocytes in the pathogenesis of asthma and COPD","volume":"14","author":"Baraldo","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.3389\/fimmu.2018.02231","article-title":"Chimeric antigen receptors based on low affinity mutants of Fc\u03b5RI re-direct T cell specificity to cells expressing membrane IgE","volume":"9","author":"Ward","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3389\/fimmu.2017.01125","article-title":"Chimeric antigen receptor-redirected regulatory T cells suppress experimental allergic airway inflammation, a model of asthma","volume":"8","author":"Skuljec","year":"2017","journal-title":"Front. Immunol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1493\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:39:16Z","timestamp":1760139556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":217,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["biomedicines10071493"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10071493","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,24]]}}}